Figure 12From: Perlecan domain 1 recombinant proteoglycan augments BMP-2 activity and osteogenesisHistomorphometric summary of conditons that included a BMP-2 dose of 50 μg per ml TCP volume (n = 25). Measured was % increase in maxillary ridge height (y-axis) relative to the conditions where BMP-2 was combined with either empty-vector plasmid, no plasmid, or the pln.247 plasmid.Back to article page